ATE205531T1 - Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum - Google Patents
Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstumInfo
- Publication number
- ATE205531T1 ATE205531T1 AT94909270T AT94909270T ATE205531T1 AT E205531 T1 ATE205531 T1 AT E205531T1 AT 94909270 T AT94909270 T AT 94909270T AT 94909270 T AT94909270 T AT 94909270T AT E205531 T1 ATE205531 T1 AT E205531T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibition
- growth
- cell activation
- antibodies
- cd2a
- Prior art date
Links
- 230000007896 negative regulation of T cell activation Effects 0.000 title 1
- 230000017066 negative regulation of growth Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2700893A | 1993-03-05 | 1993-03-05 | |
| US11903293A | 1993-09-09 | 1993-09-09 | |
| PCT/IB1994/000043 WO1994020619A1 (en) | 1993-03-05 | 1994-03-04 | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T-CELL ACTIVATION AND PROLIFERATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE205531T1 true ATE205531T1 (de) | 2001-09-15 |
Family
ID=26701922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94909270T ATE205531T1 (de) | 1993-03-05 | 1994-03-04 | Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0687300B1 (de) |
| JP (2) | JP3711143B2 (de) |
| AT (1) | ATE205531T1 (de) |
| AU (1) | AU686600B2 (de) |
| CA (1) | CA2157500C (de) |
| DE (1) | DE69428272T2 (de) |
| DK (1) | DK0687300T3 (de) |
| ES (1) | ES2164699T3 (de) |
| PT (1) | PT687300E (de) |
| WO (1) | WO1994020619A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| DK0959899T3 (da) * | 1996-08-16 | 2009-09-07 | Biotransplant Inc | LO-CD2a-antistof samt dets anvendelse til h mning af T-celleaktivering og -proliferation |
| AU750891B2 (en) | 1996-12-06 | 2002-08-01 | Aventis Pharmaceuticals Inc. | Polypeptides encoded by a human lipase-like gene, compositions and methods |
| US7008776B1 (en) | 1996-12-06 | 2006-03-07 | Aventis Pharmaceuticals Inc. | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
| JP4808841B2 (ja) * | 1997-07-18 | 2011-11-02 | バイオトランスプラント，インコーポレイテッド | Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法 |
| US6558662B2 (en) | 1997-11-14 | 2003-05-06 | The General Hospital Corporation | Treatment of hematologic disorders |
| CA2497628A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| KR101240206B1 (ko) | 2010-10-05 | 2013-03-06 | 고려대학교 산학협력단 | 자연살상 세포-매개 면역반응 억제용 조성물 |
| CN111670200A (zh) * | 2017-11-29 | 2020-09-15 | 美真达治疗公司 | 用于耗尽cd2+细胞的组合物和方法 |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4381292A (en) * | 1980-11-14 | 1983-04-26 | The Board Of Trustees Of The Leland Stanford Jr. University | Anti-human T-lymphocyte monoclonal antibody |
-
1994
- 1994-03-04 ES ES94909270T patent/ES2164699T3/es not_active Expired - Lifetime
- 1994-03-04 AU AU62181/94A patent/AU686600B2/en not_active Ceased
- 1994-03-04 AT AT94909270T patent/ATE205531T1/de not_active IP Right Cessation
- 1994-03-04 WO PCT/IB1994/000043 patent/WO1994020619A1/en active IP Right Grant
- 1994-03-04 EP EP94909270A patent/EP0687300B1/de not_active Expired - Lifetime
- 1994-03-04 DK DK94909270T patent/DK0687300T3/da active
- 1994-03-04 PT PT94909270T patent/PT687300E/pt unknown
- 1994-03-04 CA CA002157500A patent/CA2157500C/en not_active Expired - Fee Related
- 1994-03-04 JP JP51978094A patent/JP3711143B2/ja not_active Expired - Fee Related
- 1994-03-04 DE DE69428272T patent/DE69428272T2/de not_active Expired - Lifetime
-
2005
- 2005-03-07 JP JP2005062737A patent/JP4195453B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4195453B2 (ja) | 2008-12-10 |
| ES2164699T3 (es) | 2002-03-01 |
| AU6218194A (en) | 1994-09-26 |
| CA2157500C (en) | 2005-08-16 |
| CA2157500A1 (en) | 1994-09-15 |
| AU686600B2 (en) | 1998-02-12 |
| DK0687300T3 (da) | 2001-12-31 |
| WO1994020619A1 (en) | 1994-09-15 |
| PT687300E (pt) | 2002-03-28 |
| DE69428272T2 (de) | 2002-06-27 |
| JP2005239725A (ja) | 2005-09-08 |
| EP0687300B1 (de) | 2001-09-12 |
| JPH08507438A (ja) | 1996-08-13 |
| JP3711143B2 (ja) | 2005-10-26 |
| DE69428272D1 (de) | 2001-10-18 |
| EP0687300A1 (de) | 1995-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE395081T1 (de) | Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum | |
| AU7079396A (en) | Anti-galalpha(1,3)gal antibody binding peptides | |
| ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
| DK0741784T3 (da) | Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler | |
| DK0592521T3 (da) | Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler | |
| ATE132197T1 (de) | Monoklonale antikörper | |
| ATE205531T1 (de) | Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum | |
| EP0313378A3 (de) | Methoden und Zusammensetzungen für vorübergehende Elimination von humoralen immunen Antikörpern | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| DK0859957T3 (da) | Patientspecifikke immunadsorbenser til ekstraporal apherese og fremgangsmåde til deres fremstilling | |
| AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
| ATE220331T1 (de) | Cd40 bindendes protein zur stimulierung der immunantwort | |
| ATE442157T1 (de) | Verwendung von anti-cd3 monoklonale antikírper und il-5 zur behandlung von autoimmunkrankheiten | |
| ATE432080T1 (de) | Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation | |
| DE69638145D1 (de) | Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen | |
| DE69131253D1 (de) | Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein | |
| ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
| DE69221605T2 (de) | Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm) | |
| EP0321094A3 (de) | Behandlung von Faktor-VIII-Inhibitoren | |
| DE69010897D1 (de) | Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin. | |
| ATE99333T1 (de) | Immunogen und seine verwendung zur gewinnung von antikoerpern gegen haemoglobin a1c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |